Table E3.

Inhibition of allergic patients' IgE binding to Phl p 6 with IgG specific for rPhl p 6 or for Phl p 6 peptides (P1-6 to P4-6)

Patient no.	OD	rPhl p 6 (%)	P1-6 (%)	P2-6 (%)	P3-6 (%)	P4-6 (%)
1	0.304	80.14	81.69	73.38	10.17	63.26
2	0.650	92.92	86.14	91.53	1.36	41.12
3	0.455	85.95	88.58	87.37	27.43	59.84
4	0.450	67.74	66.10	63.30	25.99	36.67
5	0.332	74.02	61.99	53.38	18.54	27.29
6	0.719	70.61	73.46	65.03	13.00	53.39
7	0.279	75.96	76.78	67.51	36.49	67.96
8	0.276	41.22	34.88	7.99	31.30	19.01
9	1.669	93.29	88.16	86.06	44.83	71.19
10	1.913	85.96	80.94	85.75	0.00	21.04
11	0.258	66.75	47.34	57.04	12.25	22.89
12	0.123	45.17	61.05	29.00	27.42	43.47
13	0.275	40.27	47.92	43.45	0.00	30.86
14	0.110	94.34	93.55	93.01	27.34	67.21
15	2.014	83.13	68.82	73.71	35.92	61.12
Mean	0.65	73.17	70.50	65.17	20.80	45.75

Displayed are Phl p 6–specific IgE levels (OD levels: first column, noninhibited) for 15 patients and percentages of inhibition of IgE binding after preincubation with allergen- or peptide-specific IgG. Mean values are shown in the bottom line.